These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 6861089)
1. Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms. Prout GR; Griffin PP; Daly JJ; Heney NM Cancer; 1983 Aug; 52(3):524-32. PubMed ID: 6861089 [TBL] [Abstract][Full Text] [Related]
2. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. Solsona E; Iborra I; Rubio J; Casanova J; Almenar S BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101 [TBL] [Abstract][Full Text] [Related]
3. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma. Raman JD; Sosa RE; Vaughan ED; Scherr DS Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658 [TBL] [Abstract][Full Text] [Related]
4. [A case of transitional cell carcinoma with squamous differentiation which developed squamous cell carcinoma in situ in the clinical course]. Sugiura S; Makiyama K; Yokomizo Y; Umemoto S; Miyoshi Y; Nakaigawa N; Ogawa T; Uemurai H; Yao M; Kubota Y; Yamanaka S Hinyokika Kiyo; 2006 Sep; 52(9):715-8. PubMed ID: 17040058 [TBL] [Abstract][Full Text] [Related]
5. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Shen SS; Lerner SP; Muezzinoglu B; Truong LD; Amiel G; Wheeler TM Hum Pathol; 2006 Jun; 37(6):726-34. PubMed ID: 16733214 [TBL] [Abstract][Full Text] [Related]
6. Impact of second opinion pathology in the definitive management of patients with bladder carcinoma. Coblentz TR; Mills SE; Theodorescu D Cancer; 2001 Apr; 91(7):1284-90. PubMed ID: 11283928 [TBL] [Abstract][Full Text] [Related]
9. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Shariat SF; Kim JH; Andrews B; Kattan MW; Wheeler TM; Kim IY; Lerner SP; Slawin KM Cancer; 2001 Dec; 92(12):2985-92. PubMed ID: 11753975 [TBL] [Abstract][Full Text] [Related]
10. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Shariat SF; Palapattu GS; Karakiewicz PI; Rogers CG; Vazina A; Bastian PJ; Schoenberg MP; Lerner SP; Sagalowsky AI; Lotan Y Eur Urol; 2007 Jan; 51(1):152-60. PubMed ID: 17011114 [TBL] [Abstract][Full Text] [Related]
11. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ. Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389 [TBL] [Abstract][Full Text] [Related]
12. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder. May M; Nitzke T; Helke C; Vogler H; Hoschke B Scand J Urol Nephrol; 2004; 38(3):231-5. PubMed ID: 15204377 [TBL] [Abstract][Full Text] [Related]
13. [Transitional cell carcinoma of the prostate in cystoprostatectomy specimens]. Liedberg F; Chebil G; Davidsson T; Malmström PU; Sherif A; Månsson W Aktuelle Urol; 2003 Sep; 34(5):333-6. PubMed ID: 14566661 [TBL] [Abstract][Full Text] [Related]
14. Superficial urinary bladder cancer. Results from the Finnbladder studies and a review on instillation treatments. Jauhiainen K; Rintala E Ann Chir Gynaecol Suppl; 1993; 206():31-8. PubMed ID: 8291866 [TBL] [Abstract][Full Text] [Related]
15. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252 [TBL] [Abstract][Full Text] [Related]
16. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101 [TBL] [Abstract][Full Text] [Related]
17. Carcinoma in situ of the urinary bladder. Effect of associated neoplastic lesions on clinical course and treatment. Fukui I; Yokokawa M; Sekine H; Yamada T; Hosoda K; Ishiwata D; Oka K; Sarada T; Tohma T; Yamada T Cancer; 1987 Jan; 59(1):164-73. PubMed ID: 3791145 [TBL] [Abstract][Full Text] [Related]
18. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480 [TBL] [Abstract][Full Text] [Related]
19. Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. Hassan JM; Cookson MS; Smith JA; Johnson DL; Chang SS J Urol; 2004 Sep; 172(3):882-4. PubMed ID: 15310989 [TBL] [Abstract][Full Text] [Related]
20. Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy. Saika T; Tsushima T; Nasu Y; Arata R; Kaku H; Kusaka N; Kumon H Jpn J Clin Oncol; 2002 Nov; 32(11):461-5. PubMed ID: 12499418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]